China, Aug. 13 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Ib/II phase clinical study of AK138D1 monotherapy or in combination with evosizumab for the treatment of advanced breast cancer'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600129968
Registration Time: 2026/08/12
Type: Interventional study
Primary Sponsor: Harbin Medical University Affiliated Cancer Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=321784
Published by HT Digital Content Services with permission from Health Daily Digest....